

Holbæk-modellens effekt på fedt i leveren

Maria Martens Fraulund


læge, Ph.d.-studerende, forperson for Adipostiasudvalget i DPS


Enheden for Børn og Unge med Adipositas, Holbæk Sygehus

Kontakt: mamala@regionsjaelland.dk

Komplikationer til adipositas hos børn/unge

- 75% med nedsat selvværd, selvtillid eller livskvalitet *Fogh, J Paediatr Child Health. 2020; 56(4):542-549*
- 82% med forstyrret spisning *Fogh, J Paediatr Child Health. 2020; 56(4):542-549*
- 50% med forhøjet blodtryk *Mollerup, J Hum Hypertens. 2017;31(10):640-646*
- 28% med forhøjet kolesterol *Nielsen, BMC Pediatr. 2017 Apr 28;17(1):116*
- 60% med lavt D-vitamin *Plesner, J Pediatr Endocrinol Metab. 2018;26;31(1):53-61*
- 14% med prædiabetes *Kloppenborg, Pediatr Diabetes. 2018 May;19(3):356-365*
- 45% med søvnapnø *Andersen, Eur Arch Otorhinolaryngol. 2019 Mar;276(3):871-878*
- 31% med fedtlever *Fonvig, PLoS One. 2015 Aug 7;10(8):e0135018*






Fedt i leveren


Kendetegnet ved:

- Tilstand med øget opbevring af fedt i leveren.
- Kan udvikle sig med inflammation, fibrose og cirrose.
- Tæt relation til adipositas



Steatotisk leversygdom

- nomenklatur




Mary E. Rinella et al.: A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Journal of Hepatology, Volume 79, Issue 6, December 2023, Pages 1542-1556

*Cardiometaabolic criteria	
Adult Criteria	Pediatric Criteria
At least 1 out of 5:	At least 1 out of 5:
<input type="checkbox"/> BMI $\geq 25 \text{ kg/m}^2$ [23 Asia] OR WC $> 94 \text{ cm}$ (M) 80 cm (F) OR ethnicity adjusted	<input type="checkbox"/> BMI $\geq 85^{\text{th}} \text{ percentile}$ for age/sex [BMI z score $\geq +1$] OR WC $> 95^{\text{th}} \text{ percentile}$ OR ethnicity adjusted
<input type="checkbox"/> Fasting serum glucose $\geq 5.6 \text{ mmol/L}$ [100 mg/dL] OR 2-hour post-load glucose levels $\geq 7.8 \text{ mmol/L}$ [$\geq 140 \text{ mg/dL}$] OR HbA1c $\geq 5.7\%$ [39 mmol/L] OR type 2 diabetes OR treatment for type 2 diabetes	<input type="checkbox"/> Fasting serum glucose $\geq 5.6 \text{ mmol/L}$ [$\geq 100 \text{ mg/dL}$] OR serum glucose $\geq 11.1 \text{ mmol/L}$ [$\geq 200 \text{ mg/dL}$] OR 2-hour post-load glucose levels $\geq 7.8 \text{ mmol/L}$ [$\geq 140 \text{ mg/dL}$] OR HbA1c $\geq 5.7\%$ [39 mmol/L] OR already diagnosed/treated type 2 diabetes OR treatment for type 2 diabetes
<input type="checkbox"/> Blood pressure $\geq 130/85 \text{ mmHg}$ OR specific antihypertensive drug treatment	<input type="checkbox"/> Blood pressure age $< 13\text{y}$, BP $\geq 95^{\text{th}} \text{ percentile}$ OR $\geq 130/80 \text{ mmHg}$ (whichever is lower); age $\geq 13\text{y}$, $130/85 \text{ mmHg}$ OR specific antihypertensive drug treatment
<input type="checkbox"/> Plasma triglycerides $\geq 1.70 \text{ mmol/L}$ [150 mg/dL] OR lipid lowering treatment	<input type="checkbox"/> Plasma triglycerides $< 10\text{y}$, $\geq 1.15 \text{ mmol/L}$ $[> 100 \text{ mg/dL}]$; age $\geq 10\text{y}$, $\geq 1.70 \text{ mmol/L}$ $[> 150 \text{ mg/dL}]$ OR lipid lowering treatment
<input type="checkbox"/> Plasma HDL-cholesterol $\leq 1.0 \text{ mmol/L}$ [40 mg/dL] (M) $\text{and } \leq 1.3 \text{ mmol/L}$ [50 mg/dL] (F) OR lipid lowering treatment	<input type="checkbox"/> Plasma HDL-cholesterol $\leq 1.0 \text{ mmol/L}$ [$\leq 40 \text{ mg/dL}$] OR lipid lowering treatment




Undersøgelsesmetoder


- Leverbiopsi



- Ultralyd




- MR-Imaging
- MR-Spektroskopi



Baggrund

- Børn/unge med adipositas har øget risiko for komplikationer
- Fedt i og omkring organerne giver øget risiko for kardiometabolisk sygdom og organskade.
- Fedt i leveren er forbundet med metabolisk dysfunktion.
- Steatotisk leversygdom kan opstå allerede i barndommen
 - Prævalensen øges med alderen, hos drenge og samtidig adipositas*.



* Cholongitas E, et al. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol, 2021;
Wiegand S, et al. Obese boys at increased risk for nonalcoholic liver disease: Evaluation of 16 390 overweight or obese children and adolescents. Int J Obes. 2010



Tidlige studier



RESEARCH ARTICLE

¹H-MRS Measured Ectopic Fat in Liver and Muscle in Danish Lean and Obese Children and Adolescents

Cilius Esman Fonvig^{1,2*}, Elizaveta Chabanova³, Flem Astrøm Dam Øhr¹, Olfud Pedersen⁴, Torben Hansen^{2,4}, Henrik S. Thomsen⁵, Christian Holm⁶

¹ The Children's Obesity Clinic, Department of Pediatrics, Copenhagen University Hospital Hvidovre, Copenhagen, Denmark; ² Metabolic Genetics, Faculty of Medical and Health Sciences, University of Copenhagen, Copenhagen, Denmark; ³ Department of Diagnostic Radiology, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark; ⁴ University of Southern Denmark, Faculty of Health Sciences, Odense, Denmark; ⁵ Copenhagen, Faculty of Medical and Health Sciences, Copenhagen N, Copenhagen, Denmark

* cfro@regionh.region.jysk.dk

Abstract

This cross-sectional study aims to investigate the association between anthropometry, blood pressure, and magnetic resonance spectroscopy in lean and obese children and adolescents using indices of body composition.

Methods
Fasting plasma glucose, serum lipids, serum insulin, and expanthropometry, blood pressure, and magnetic resonance spectroscopy were obtained in 327 Danish children and adolescents aged 6–18 years.

Results
In 287 overweight/obese children, the prevalences of hepatic steatosis were 31% and 68%, respectively, whereas the prevalences in 40 lean children were 10%. A multiple regression analysis adjusted for z-score (BMI SDS), and pubertal development showed that the OR for developing dyslipidemia was 4.2 (95%CI: [1.8, 10.2], $p = 0.0009$) when hepatic steatosis and the simultaneous presence of hepatic and muscular steatosis, the OR of developing dyslipidemia was 5.8 (95%CI: [1.1, 24.0], $p < 0.0001$). Significant associations between muscle fat and dyslipidemia, or blood pressure were observed.

Liver and muscle fat, adjusted for age, sex, BMI SDS, and adjusted to BMI SDS and glycosylated hemoglobin, while only liver fat was obtained in 327 Danish children and adolescents aged 6–18 years.

Conclusion
Liver and muscle fat, adjusted for age, sex, BMI SDS, and adjusted to BMI SDS and glycosylated hemoglobin, while only liver fat was obtained in 327 Danish children and adolescents aged 6–18 years.

Funding
This study was funded by the Danish Innovation Foundation (grant number 0603-00484B) and by the Region Zealand Health and Medical Research Foundation (TH-CF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.



OPEN ACCESS

Citation: Fonvig CE, Chabanova E, Andersen EA, Øhr JD, Pedersen O, Hansen T, et al. (2015) ¹H-MRS Measured Ectopic Fat in Liver and Muscle in Danish Lean and Obese Children and Adolescents. PLoS ONE 10(8): e0135018. doi:10.1371/journal.pone.0135018

Editor: Marie Therese, NIH / NIDDK, UNITED STATES

Received: March 9, 2015

Accepted: July 18, 2015

Published: August 7, 2015

Copyright: © 2015 Fonvig et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are available from the Danish Obesity Registry Biobank database for researchers who need the criteria for diagnosis to confirm their data. Access may be acquired through contact to: cfro@regionh.region.jysk.dk.

Funding: This study was funded by the Danish Innovation Foundation (grant number 0603-00484B) and by the Region Zealand Health and Medical Research Foundation (TH-CF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

PLOS ONE | DOI:10.1371/journal.pone.0135018 August 7, 2015

Received: 12 May 2021 | Revised: 5 May 2022 | Accepted: 9 May 2022
DOI: 10.1111/po.12947

ORIGINAL RESEARCH

Possible prediction of obesity-related liver disease in children and adolescents using indices of body composition

Magnus Jung Johansen¹ ● Morten Asp Vonsild Lund^{1,2} ● Lars Ångquist³ ● Cilius Esman Fonvig^{1,3} ● Louise Aas Holm^{1,3} ● Elizaveta Chabanova⁴ ● Henrik S. Thomsen^{4,5} ● Torben Hansen^{3,6} ● Jens-Christian Holm^{1,3,5}

¹The Children's Obesity Clinic, Accredited European Centre for Obesity Management, Department of Pediatrics, Copenhagen University Hospital Holbæk, Holbæk, Denmark

²Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

³The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

⁴Department of Radiology, Herlev Gentofte Hospital, Herlev, Denmark

⁵Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

⁶Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Summary
Background: Diagnosis of nonalcoholic fatty liver disease in children and adolescents currently requires advanced or invasive technologies.

Objectives: We aimed to develop a method to improve diagnosis, using body composition indices and liver biochemical markers.

Methods: To diagnose non-alcoholic fatty liver disease, 767 Danish children and adolescents underwent clinical examination, blood sampling, whole-body dual-energy X-ray absorptiometry scanning and proton magnetic resonance spectroscopy for liver fat quantification.

Fourteen variables were selected as a starting point to construct models, narrowed by stepwise selection. Individuals were split into a training set for model construction and a validation test set. The final models were applied to 2120 Danish children and adolescents to estimate the prevalence.

Results: The final models included five variables in different combinations: body mass index-standard deviation score, android-to-gynoid-fat ratio, android-regional fat percent, trunk-regional fat percent and alanine transaminase. When validated, the sensitivity and specificity ranged from 38.6% to 51.7% and 87.6% to 91.9%, respectively.

The estimated prevalence was 24.2%–35.3%. Models including alanine transaminase alongside body composition measurements displayed higher sensitivity.

Conclusions: Body composition indices and alanine transaminase can be used to estimate non-alcoholic fatty liver disease, with 38.6%–51.7% sensitivity and 87.6%–91.9% specificity, in children and adolescents with overweight (including obesity).

These estimated a 24.2%–35.3% prevalence in 2120 patients.

Keywords
adolescents, body composition, children, DXA-scan, MAFLD, NAFLD

Abbreviations: ¹H-MRS, proton magnetic resonance spectroscopy; AIC, Alkaline information criterion; ALT, alanine transaminase; AUC, area under the curve; BMI-SDS, body mass index-standard deviation score; DXA, dual-energy X-ray absorptiometry; MAFLD, metabolic dysfunction-associated fatty liver disease; NAFLD, non-alcoholic fatty liver disease; NMR, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; VAT, visceral adipose tissue.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

Pediatric Obesity, 2022;17:e12947.
https://doi.org/10.1111/po.12947

Fonvig et al. BMC Pediatrics (2015) 15:196
DOI 10.1186/s12887-015-0513-6

BMC Pediatrics

RESEARCH ARTICLE

Multidisciplinary care of obese children and adolescents for one year reduces ectopic fat content in liver and skeletal muscle

Elizaveta Chabanova³, Johanne Dam Øhr¹, Louise Aas Nielsen^{1, C}
Christian Holm^{1,4}

¹ The Children's Obesity Clinic, Holbæk, Denmark

² Department of Radiology, Bispebjerg Hospital, Copenhagen, Denmark

³ Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

⁴ Department of Pediatrics, Holbæk Hospital, Part of Ulstein Hospital, Kolding, Denmark

⁵ Copenhagen University Hospital Gentofte, Copenhagen, Denmark

⁶ Department of Congenital Disorders, Steno's Serum Institute, Copenhagen, Denmark

⁷ Department of Diagnostic Radiology, Copenhagen University Hospital Gentofte, Copenhagen, Denmark

⁸ Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark

⁹ Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

¹⁰ Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark

Open Access



RESEARCH ARTICLE

An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents

Yun Huang¹ ● Sara E. Stinson¹ ● Helene Bæk Juel¹ ● Morten A. V. Lund^{2,3} ● Louise Aas Holm^{1,2} ● Cilius E. Fonvig^{1,2,4} ● Trine Nielsen¹ ● Niels Grarup¹ ● Olfud Pedersen^{1,5} ● Michael Christiansen^{3,6} ● Elizaveta Chabanova⁷ ● Henrik S. Thomsen⁷ ● Aleksander Krag^{8,9} ● Stefan Stender¹⁰ ● Jens-Christian Holm^{1,2} ● Torben Hansen¹

¹Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

²The Children's Obesity Clinic, Accredited European Centre for Obesity Management, Department of Pediatrics, Copenhagen University Hospital Holbæk, Copenhagen, Denmark

³Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

⁴Department of Pediatrics, Holbæk Hospital, Part of Ulstein Hospital, Kolding, Denmark

⁵Copenhagen University Hospital Gentofte, Copenhagen, Denmark

⁶Department of Congenital Disorders, Steno's Serum Institute, Copenhagen, Denmark

⁷Department of Diagnostic Radiology, Copenhagen University Hospital Gentofte, Copenhagen, Denmark

⁸Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark

⁹Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

¹⁰Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark

Correspondence

Torben Hansen

Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 18, 2100 Copenhagen, Denmark

E-mail: torben.hansen@regionh.dk

Funding information

The Novo Nordisk Foundation, Grant/

Project ID: 2014-004548

The Novo Nordisk Foundation, Grant/Award Number: NNFI50C0016544

The MicroLiver Challenge, Grant/Award Number: NNFI50C0001692

Abbreviations: ¹H-MRS, proton magnetic resonance spectroscopy; ALT, alanine transaminase; AUC, area under the curve; BMI-SDS, body mass index-standard deviation score; DXA, dual-energy X-ray absorptiometry; MAFLD, metabolic dysfunction-associated fatty liver disease; NAFLD, non-alcoholic fatty liver disease; NMR, negative predictive value; PPV, positive predictive value; ROC, receiver operating characteristic; VAT, visceral adipose tissue.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background & Aims: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background & Aims: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background & Aims: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background & Aims: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background & Aims: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background & Aims: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

Background: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.


Background & Aims: Genome-wide association studies have identified steatogenic variants that also showed pleiotropic effects on cardiometabolic traits in adults. We investigated the effect of eight previously reported genome-wide significant steatogenic variants, individually and combined in a weighted genetic risk score (GRS), on liver and cardiometabolic traits, and the predictive ability of the GRS for hepatic steatosis in children and adolescents.

Approach & Results: Children and adolescents with overweight (including obesity) from an obesity clinic group ($n = 178$) and a population-based group ($n = 1890$) were included. Cardiometabolic risk outcomes and genotypes were obtained. Liver fat was quantified using ¹H-MRS in a subset of 727 participants. Variants in PNPLA3, TM6SF2,

and FEN1 were associated with liver fat.

Conclusion: An adult-based genetic risk score for liver fat associates with liver and plasma lipid traits in children and adolescents.

The HOLBAEK Study, The Children's Obesity Clinic



Resultater


Baseline

n=3,120



Børn/unge med adipositas
& MR ved opstart

n=1,002 med MRS



Alder: 13 år

BMI SDS: 2.90

Livvidde: 2.42

Sammenligningsgruppen
(Børn/unge med overvægt)

n=2,118 (ingen MRS)



Alder: 12 år

BMI SDS: 2.93

Livvidde: 2.45




Børn/unge med adipositas
& MR ved opstart
 $n=1,002$



Børn/unge
MED fedt i leveren

$n=378$



Alder: 13.4 år

BMI SDS: 3.20

Livvidde SDS: 2.62

$p = 0.02$

$p < 0.001$

$p < 0.001$

Børn/unge
UDEN fedt i leveren

$n=624$



Alder: 12.9 år

BMI SDS: 2.75

Livvidde SDS: 2.27



Table 1 – Study group characteristics at baseline


		Overall	MASLD (LFC>1.5%)	No MASLD	p-value
n		1,002	378	624	
Sex – female, n (%)		525 (52.4)	172 (45.5)	353 (56.6)	0.001
Age (years), median [IQR]		13.0 [11.3, 15.0]	13.4 [11.4, 15.4]	12.9 [11.3, 14.8]	0.02
Social class ^a , n (%)					0.046
High class		85 (9.7)	24 (7.5)	61 (11.0)	
Higher middle class		198 (22.6)	60 (18.7)	138 (24.9)	
Middle class		335 (38.2)	129 (40.2)	206 (37.1)	
Lower middle class		160 (18.3)	66 (20.6)	94 (16.9)	
Lower class		98 (11.2)	42 (13.1)	56 (10.1)	
Ethicity, n (%)					0.008
Causasian		896 (89.4)	323 (85.4)	573 (91.8)	
Middle Eastern		83 (8.3)	44 (11.6)	39 (6.2)	
Asian		6 (0.6)	4 (1.1)	2 (0.3)	
African		14 (1.4)	5 (1.3)	9 (1.4)	
Hispanic		3 (0.3)	2 (0.5)	1 (0.2)	
Pubertal status ^b , n (%)					0.87
Prepubertal		138 (24.7)	49 (25.4)	89 (24.4)	
Peripubertal		259 (46.4)	91 (47.2)	168 (46.0)	
Postpubertal		161 (28.9)	53 (27.5)	108 (29.6)	
BMI z-score, median [IQR]		2.90 [2.49, 3.34]	3.20 [2.78, 3.60]	2.76 [2.37, 3.15]	<0.001
Waist circumference z-score, median [IQR]		2.42 [2.02, 2.73]	2.62 [2.31, 2.88]	2.27 [1.90, 2.60]	<0.001
Waist-height ratio, median [IQR]		0.59 [0.54, 0.64]	0.62 [0.58, 0.66]	0.57 [0.53, 0.62]	<0.001
LFC, median [IQR]		1.00 [0.5, 2.80]	4.65 [2.10, 9.1]	0.50 [0.50, 1.00]	<0.001
SAT, median [IQR]		293 [222, 386]	344 [255, 456]	274 [205, 350]	<0.001
VAT, median [IQR]		70 [50, 94]	89 [68, 114]	60 [45, 80]	<0.001




145 patients med MASLD:





- **110 (76%)** reducerede deres leverfedt indhold
- 33 øgede LFC
- **59 (53%)** af de 110 havde ingen MASLD ved follow-up

Ændring i leverfedt indhold (LFC) i 145 patienter MED MASLD ($LFC > 1.5\%$)



Change in LFC





Tak til:

- Jens-Christian Holm, læge, PhD, Assoc. Prof., Holbæk
- Cilius Esmann Fonvig, læge, PhD, Holbæk
- Rebecca Berg Pedersen, Stud.med., Holbæk
- Elizaveta Hansen, MR fysiker, Herlev
- Henrik Thomsen, læge, Prof., Herlev
- Enheden for Børn og Unge med Adipositas, Holbæk
- The HOLBAEK Study
- Alle deltagende børn og unge

